

## Opioid Antagonist Products

### Naloxone Products

Formulation	One-Step Intranasal Spray Devices						Injectable Solution	Prefilled Syringe Injector
<b>Product</b>	RiVive	Narcan Nasal Spray	Generic 4 mg nasal spray	Rextovy	Kloxxado	Rezenopy	Generic	Zimhi
<b>Rx/OTC</b>	OTC	OTC	OTC	Rx	Rx	Rx	Rx	Rx
<b>NDC</b>	82954-0100-01	69547-0627-02	Amneal: 69238-2104-07 Padagis: 45802-0578-84 Teva: 00480-3478-68	76329-3669-02	59467-0679-01	43674-0003-02	Many NDCs	38739-0600-01 38739-0600-02
<b>Manufacturer</b>	Harm Reduction Therapeutics	Emergent	Refer to NDC	Amphastar	Hikma	Summit Biosciences	Many manufacturers	Adamis
<b>Strength</b>	3mg/0.1 mL	4 mg/0.1 mL	4 mg/0.1 mL	4 mg/0.25 mL	8 mg/0.1 mL	10 mg/0.11 mL	0.4 mg/mL or 1 mg/mL	5 mg/0.5 mL
<b>Packaging/Qty</b>	2 nasal spray units per box						Single-dose flip-top vials (1 mL) or single-dose prefilled syringes (2 mL)	One-pack, two-pack
<b>Directions for Administration</b>	Spray contents of device into one nostril. Repeat with second device into other nostril after 2-3 minutes if no or minimal response.						Administer 1 mL IV (preferred) or IM. Repeat after 2-3 minutes if no or minimal response.	Inject 0.5 mL in upper thigh. Repeat with new prefilled syringe after 2-3 minutes if no or minimal response.
<b>Storage</b>	Store at room temperature; protect from light							

Last reviewed December 4, 2024



**HEALing Communities Study Kentucky**  
Prescription Opioid Safety Educational Outreach Program

## Opioid Antagonist Products

### Nalmefene Products

Formulation	One-Step Intranasal Spray	Injectable Solution		Prefilled Auto-Injector
<b>Product</b>	Opvee®	Generic	Generic	Zurnai
<b>Rx/OTC</b>	Rx	Rx	Rx	Rx
<b>NDC</b>	75095-0003-02	Purdue Pharma: 59011-0960-10 Chengdu Shuode: 82432-0102-02 (green label)	82432-0101-01 (blue label)	59011-0962-01
<b>Manufacturer</b>	Indivior	Refer to NDC	Chengdu Shuode	Purdue Pharma
<b>Strength</b>	2.7 mg/0.1 mL	2 mg/2 mL (1 mg/mL)	100 µg/mL	1.5 mg/0.5 mL
<b>Dose</b>	2.7 mg	<b>Without opioid dependency</b> , 0.5 mg/70 kg; if no response, may administer 1.0 mg/70 kg 2-5 min later <b>Known or suspected opioid dependency</b> , challenge dose of 0.1 mg/70 kg; if no evidence of withdrawal within 2 minutes, proceed with 0.5 mg/70 kg; if no response, may administer 1.0 mg/70 kg 2-5 min later		1.5 mg
<b>Directions for Administration</b>	Administer 0.1 mL (single spray) intranasally; may administer additional dose(s) every 2 to 5 min if no or minimal response.	Administer IV (preferred) or IM or SUBQ (if venous access cannot be established) using the listed dosing regimens.		Inject 0.5 mL into outer thigh by pressing the needle end firmly into injection site. Hold for 3 seconds. Repeat with new injector after 2-5 minutes if no response.
<b>Packaging/Qty</b>	2 nasal spray units/box	1 or 10 vials (2 mL)/box	1 vial (1 mL)/box	1 single dose auto-injector/box
<b>Storage</b>	Store at room temperature; protect from light			

#### References

Formulations [Internet]. PrescribeToPrevent. <https://prescribetoprevent.org/pharmacists/formulations/>. Accessed June 26, 2023; Nalmefene HCl [Internet]. Stanford (CT): Purdue Pharma L.P.; 2022. <https://nalmefenehcl.com>. Accessed June 26, 2023; Nalmefene. In: Lexi-Drugs Online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2023. <http://online.lexi.com>. Accessed June 26, 2023; Naloxone. In: Lexi-Drugs Online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2023. <http://online.lexi.com>. Accessed June 26, 2023; Opvee [Internet]. North Chesterfield (VA): Indivior Inc.; 2023. <https://opvee.com>. Accessed June 26, 2023. Drugs@FDA <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed November 22, 2024.

Last reviewed December 4, 2024



**HEALing Communities Study Kentucky**  
Prescription Opioid Safety Educational Outreach Program